Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the treatment and prevention of addictions. The Company’s lead investigational new drug product, AD04, is currently in Phase 3 development as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency and quantity of drinking and heavy drinking with no overt safety concerns.
Genetically Targeted
Designed to reduce craving to effectively curb alcohol intake in those patients with the genetics expected to indicate a likely response to treatment with AD04
BRINGS 20+ YEAR TRACK RECORD OF CLINICAL USE
To date, clinical testing of AD04 has shown it to have a positive safety and tolerability profile with side effects similar to placebo.
Oral daily dosing
Our product candidate is intended to be easy to use since it is administered orally.
AUD is characterized by an urge to consume alcohol and an inability to control the levels of consumption
Email Alerts
SIGN UP TODAYLatest Tweets
Our CEO @BillStilley spoke with @AuthorityMgzine about what inspired him to co-found Adial to develop potential treatments for #addictions & the ...rise in #AlcoholUseDisorder as a result of the COVID-19 pandemic. $ADIL #AlcoholAwarenessMonth #HiddenPandemic
Heroes Of The Addiction Crisis: How William ”Bill” Stilley of Adial Pharmaceuticals Is Helping Toâ¦
The pandemic is creating an explosion of addiction, and mental health disorders in general. Think about this for a...
medium.com
With a recent study published in JAMA Network Open finding that alcohol consumption had increased 41% increase among women in 2020 over 2019, proper ...screening and referrals will be crucial.
Healthcare professionals can use this guide for prevention and treatment of risky drinking in women, from #NASW, @NASWFoundation, and @TexasSteveHicks’ Health Behavior Research and Training Institute: https://bit.ly/3ujYcVj #AlcoholAwarenessMonth #FASDchat https://twitter.com/acog/status/1379836370718494720
Studies show that #women start to have #alcohol-related problems sooner and at lower #drinking levels than men. Get all the facts this ...#AlcoholAwarenessMonth
Studies show that #women start to have #alcohol-related problems sooner and at lower #drinking levels than men. Get all the facts this #AlcoholAwarenessMonth: https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/women-and-alcohol?utm_source=twitter&utm_medium=social&utm_campaign=apr-2021
AD04 Ready to Enter Phase 3 in Targeted Groups
Adial has commenced a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.
Adial has created an investigational attendant diagnostic biomarker blood test for the genetic screening of patients with certain biomarkers that, as reported in the American Journal of Psychiatry (Johnson, et. al. 2011 & 2013), Adial believes make patients more likely to benefit from treatment with AD04.
Adial’s strategy is to integrate pre-treatment genetic screening into AD04’s label to create a patient-specific treatment in one integrated therapeutic offering. Adial’s goal is to develop a genetically targeted, effective and safe product candidate to treat AUD that does not require abstinence as part of the treatment.